271 related articles for article (PubMed ID: 30170758)
1. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.
Marshall JC; Liang Y; Sahasrabudhe V; Tensfeldt T; Fediuk DJ; Zhou S; Krishna R; Dawra VK; Wood LS; Sweeney K
J Clin Pharmacol; 2021 Sep; 61(9):1220-1231. PubMed ID: 33813736
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
[TBL] [Abstract][Full Text] [Related]
4. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
Li Y; Mu Y; Shi H; Liang Y; Liu Z; Matschke K; Hickman A; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):97-106. PubMed ID: 30934166
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
[TBL] [Abstract][Full Text] [Related]
9. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
Dawra VK; Cutler DL; Zhou S; Krishna R; Shi H; Liang Y; Alvey C; Hickman A; Saur D; Terra SG; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2019 Apr; 8(3):314-325. PubMed ID: 29786959
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
[TBL] [Abstract][Full Text] [Related]
12. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
Callegari E; Lin J; Tse S; Goosen TC; Sahasrabudhe V
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):127-136. PubMed ID: 33314761
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.
Li Y; Nucci G; Yamamoto Y; Fediuk DJ; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):765-776. PubMed ID: 33434408
[TBL] [Abstract][Full Text] [Related]
14. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
Raje S; Callegari E; Sahasrabudhe V; Vaz A; Shi H; Fluhler E; Woolf EJ; Schildknegt K; Matschke K; Alvey C; Zhou S; Papadopoulos D; Fountaine R; Saur D; Terra SG; Stevens L; Gaunt D; Cutler DL
Clin Transl Sci; 2018 Jul; 11(4):405-411. PubMed ID: 29575530
[TBL] [Abstract][Full Text] [Related]
15. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects.
Stoch SA; Ballard J; Gibson C; Kesisoglou F; Witter R; Kassahun K; Zajic S; Mehta A; Brandquist C; Dempsey C; Stypinski D; Reitman ML
J Clin Pharmacol; 2017 Jan; 57(1):110-117. PubMed ID: 27321774
[TBL] [Abstract][Full Text] [Related]
17. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
Li T; Li X; Jiang X; Wang C; Sun F; Liu Y; Lin P; Shi P; Fu Y; Gao X; Zhang Y; Cao Y
Cancer Chemother Pharmacol; 2022 Nov; 90(5):409-415. PubMed ID: 36107220
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
